Form 4 for OVID Ovid Therapeutics Inc.
Accepted 2025-02-24 00:00:00 ET · period of report 2025-02-20 · accession 0001415889-25-005367 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-24 | 2025-02-20 | OVID | Rona Jeffrey A | CBFO | A - Grant | $0.00 | +43.8K | 71.9K | +156% | $0 |
| D | 2025-02-24 | 2025-02-20 | OVID | Rona Jeffrey A | CBFO | A - Grant | $0.00 | +262.5K | 262.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-20 | A | A | 43,750 | $0.00 | 71,875 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 22, 2026, subject to the Reporting Person's continuous service through each such vesting date. (F2) Each RSU represents a contingent right to receive one share of Common Stock. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2025-02-20 | A | A | 262,500 | $0.00 | 262,500 | D | $0.57 · — to 2035-02-19 | 262,500 Common Stock | (F3) The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date. |